Abstract: FR-PO0495
Finerenone in Asian Patients with CKD: A FIND-CKD Analysis
Session Information
- CKM: Clinical - Trials, Epidemiology, and Biomarkers
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Nangaku, Masaomi, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
- Agarwal, Rajiv, Richard L. Roudebush VA Medical Center, Indianapolis, Indiana University School of Medicine, Indianapolis, Indiana, United States
- Cherney, David, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
- Lam, Carolyn S.P., National Heart Centre Singapore, Singapore, Singapore
- Neuen, Brendon Lange, George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
- Perkovic, Vlado, Royal North Shore Hospital, Sydney, New South Wales, Australia
- Tuttle, Katherine R., Providence Inland Northwest Health, University of Washington School of Medicine, Spokane, Washington, United States
- Sarafidis, Pantelis, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
- Brinker, Meike Daniela, Bayer AG, Wuppertal, Germany
- Heerspink, Hiddo Jan L., George Institute for Global Health, University of New South Wales, Sydney, Australia
Background
Globally, Asia has one of the highest prevalences of chronic kidney disease (CKD), with the number of affected individuals increasing from an estimated 202.4 million in 1990 to 431.2 million in 2019, and projected to rise further. Effective treatment of CKD in Asian patients is critical to address the rapidly growing healthcare and socioeconomic impact of CKD across Asia. Finerenone significantly improves kidney and cardiovascular (CV) outcomes in patients with CKD, with and without type 2 diabetes. The aim of this subanalysis was to assess the efficacy and safety of finerenone in patients of the Asian subpopulation from the phase 3 FIND-CKD trial.
Methods
FIND-CKD included 1584 adults with non-diabetic CKD (estimated glomerular filtration rate [eGFR], 25 to <90 mL/min/1.73 m2), albuminuria (urinary albumin-to-creatinine ratio [UACR], 200 to ≤3500 mg/g) worldwide, including 632 in East Asia (China, Hong Kong, Taiwan, Japan and South Korea) who self-identified as Asian. Patients were on maximum tolerated renin–angiotensin system blockade and were randomized 1:1 to finerenone (10 or 20 mg oral) or placebo. Mean annual rate of eGFR change from baseline to month 32 and the composite kidney-CV outcome of a sustained ≥57% eGFR reduction from baseline, kidney failure, heart failure hospitalization or CV death were assessed. Safety outcomes were reported as treatment-emergent adverse events.
Results
Among Asian patients (finerenone: n=311 [49.2%]; placebo: n=321 [50.8%]), 62% (n=389) were male, and mean age at baseline was 53.8 years. Baseline eGFR (mean [SD]) and UACR (median [Q1–Q3]) were 47.8 [16.2] ml/min/1.73m2 and 779 [569–1164] mg/g, respectively. Finerenone reduced the rate of total eGFR decline (mL/min/1.73 m2/year), with a mean annual rate change of –3.5 (95% confidence interval (CI) –3.9, –3.1) vs placebo (–3.9 [95% CI –4.4, –3.5]) over 32 months (difference of 0.4 [95% CI –0.12, 1.00]; p=0.12) and lowered the composite kidney-CV outcome vs placebo (hazard ratio 0.60; 95% CI 0.40, 0.89). The most frequent safety event with finerenone was hyperkalemia, but events that led to hospitalization were low.
Conclusion
This subpopulation analysis demonstrated that the benefits of finerenone in Asian patients were consistent with those reported in the overall population in the FIND-CKD trial.
Funding
- Commercial Support – Bayer AG